About
Making drug discovery and development fun and engaging by optimizing connections…
Articles by Chiu,
Activity
-
I hope to meet you at PEGS Europe for insightful discussions, good stories, better meals, and potential collaborations
I hope to meet you at PEGS Europe for insightful discussions, good stories, better meals, and potential collaborations
Shared by Chiu, Mark
Experience
-
Tavotek BioTherapeutics
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
University of Illinois at Urbana-Champaign
-
Activities and Societies: Biochemistry Graduate Student Organization, Protein Society, American Chemical Society, American Physical Society, Biophysical Society
Structure function relationships of heme proteins using different spectroscopic methods
-
-
Activities and Societies: Pi Kappa Alpha, Model United Nations Secretary General, Model United Nations Debate Team, Public Affairs Office
Tour guide, learned about Biophysics, Technology, Economics, Political Science
-
-
Volunteer Experience
-
Curriculum Committee
Kenosha Unified School District
- 3 years 4 months
Education
Evaluate curriculum planning
Participate in Strategic planning for KUSD
ran numerous Science and Math nights for Elementary and Middle School -
Soccer Coach
GCVSA, TEYSA
- Present 14 years
Children
Soccer Coach
-
Knight
Knights of Columbus - Washington DC
- Present 12 years 7 months
Social Services
charities for the Chester and Delaware Counties
Publications
-
An efficient process of generating bispecific antibodies via controlled Fab-arm exchange using culture supernatants
Protein Expression and Purification
Bispecific antibody generation is actively pursued for therapeutic and research antibody development. Although there are multiple strategies for generating bispecific antibodies (bsAbs); the common challenge is to develop a scalable method to prepare bsAbs with high purity and yield. The controlled Fab-arm exchange (cFAE) method combines two parental monoclonal antibodies (mAbs), each with a matched point mutation, F405L and K409R in the respective CH3 domains. The conventional process employs…
Bispecific antibody generation is actively pursued for therapeutic and research antibody development. Although there are multiple strategies for generating bispecific antibodies (bsAbs); the common challenge is to develop a scalable method to prepare bsAbs with high purity and yield. The controlled Fab-arm exchange (cFAE) method combines two parental monoclonal antibodies (mAbs), each with a matched point mutation, F405L and K409R in the respective CH3 domains. The conventional process employs two steps: the purification of two parental mAbs from culture supernatants followed by cFAE. Following a reduction/oxidation reaction, the bispecific mAb is formed with greater than 95% heterodimerization efficiency. In this study, cFAE was initiated in culture supernatants expressing the two parental mAbs, thereby eliminating the need to first purify the parental mAbs. The bsAbs formed in culture supernatant was then purified using a Protein A affinity chromatography. The BsAbs generated in this manner had efficiency comparable to the conventional method using purified parental mAbs. BsAbs prepared by two different routes showed indistinguishable characteristics by SDS capillary electrophoresis, analytical size exclusion, and cation exchange chromatography. This alternative method significantly shortened timelines and reduced resources required for bsAb generation, providing an improved process with potential benefits in large-scale bsAb preparation, as well as for HTP small-scale bsAb matrix selection.
Other authorsSee publication -
Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody
mAbs
Multispecific proteins, such as bispecific antibodies (BsAbs), that bind to two different ligands are becoming increasingly important therapeutic agents. Such BsAbs can exhibit markedly increased target binding and target residence time when both pharmacophores bind simultaneously to their targets. The cross-arm binding efficiency (χ) describes an increase in apparent affinity when a BsAb binds to the second target or receptor (R2) following its binding to the first target or receptor (R1) on…
Multispecific proteins, such as bispecific antibodies (BsAbs), that bind to two different ligands are becoming increasingly important therapeutic agents. Such BsAbs can exhibit markedly increased target binding and target residence time when both pharmacophores bind simultaneously to their targets. The cross-arm binding efficiency (χ) describes an increase in apparent affinity when a BsAb binds to the second target or receptor (R2) following its binding to the first target or receptor (R1) on the same cell. χ is an intrinsic characteristic of a BsAb mostly related to the binding epitopes on R1 and R2. χ can have significant impacts on the binding to R2 for BsAbs targeting two receptors on the same cell. JNJ-61186372, a BsAb that targets epidermal growth factor receptor (EGFR) and c-Met, was used as the model compound for establishing a method to characterize χ. The χ for JNJ-61186372 was successfully determined via fitting of in vitro cell binding data to a ligand binding model that incorporated χ. The model-derived χ value was used to predict the binding of JNJ-61186372 to individual EGFR and c-Met receptors on tumor cell lines, and the results agreed well with the observed IC50 for EGFR and c-Met phosphorylation inhibition by JNJ-61186372. Consistent with the model, JNJ-61186372 was shown to be more effective than the combination therapy of anti-EGFR and anti-c-Met monovalent antibodies at the same dose level in a mouse xenograft model. Our results showed that χ is an important characteristic of BsAbs, and should be considered for rationale design of BsAbs targeting two membrane bound targets on the same cell.
Other authorsSee publication -
Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody
Journal of Biological Chemistry
The efficacy of engaging multiple drug targets using bispecific antibodies (BsAbs) is affected by the relative cell-surface protein levels of the respective targets. In this work, the receptor density values were correlated to the in vitro activity of a BsAb (JNJ-61186372) targeting epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-MET). Simultaneous binding of the BsAb to both receptors was confirmed in vitro. By using controlled Fab-arm exchange, a set of BsAbs…
The efficacy of engaging multiple drug targets using bispecific antibodies (BsAbs) is affected by the relative cell-surface protein levels of the respective targets. In this work, the receptor density values were correlated to the in vitro activity of a BsAb (JNJ-61186372) targeting epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-MET). Simultaneous binding of the BsAb to both receptors was confirmed in vitro. By using controlled Fab-arm exchange, a set of BsAbs targeting EGFR and c-MET was generated to establish an accurate receptor quantitation of a panel of lung and gastric cancer cell lines expressing heterogeneous levels of EGFR and c-MET. EGFR and c-MET receptor density levels were correlated to the respective gene expression levels as well as to the respective receptor phosphorylation inhibition values. We observed a bias in BsAb binding toward the more highly expressed of the two receptors, EGFR or c-MET, which resulted in the enhanced in vitro potency of JNJ-61186372 against the less highly expressed target. On the basis of these observations, we propose an avidity model of how JNJ-61186372 engages EGFR and c-MET with potentially broad implications for bispecific drug efficacy and design.
Other authorsSee publication -
The Effect of Ionic Liquids on Protein Crystallization and X-ray Diffraction Resolution
Cryst. Growth Des.
Ionic liquids exhibit a variety of properties that make them attractive solvents for biomaterials. Given the potential for productive interaction between ionic liquids and biological macromolecules, we investigated the use of ionic liquids as precipitating agents and additives for protein crystallization for six model proteins (lysozyme, catalase, myoglobin, trypsin, glucose isomerase, and xylanase). The ionic liquids produced changes in crystal morphology and mediated significant increases in…
Ionic liquids exhibit a variety of properties that make them attractive solvents for biomaterials. Given the potential for productive interaction between ionic liquids and biological macromolecules, we investigated the use of ionic liquids as precipitating agents and additives for protein crystallization for six model proteins (lysozyme, catalase, myoglobin, trypsin, glucose isomerase, and xylanase). The ionic liquids produced changes in crystal morphology and mediated significant increases in crystal size in some cases. Crystals grown using ionic liquids as precipitating agents or as additives provided X-ray diffraction resolution similar to or better than that obtained without ionic liquids. Based upon the experiments performed with model proteins, the ionic liquids were used as additives for the crystallization of the poorly diffracting monoclonal antibody 106.3 Fab in complex with the B-type natriuretic peptide (5-13). The ionic liquids improved the crystallization behavior and provided improved diffraction resulting in the determination of the structure. Ionic liquids should be considered as useful additives for the crystallization of other proteins.
-
Crystallization of bacteriorhodopsin solubilized by a tripod amphiphile
Biochim Biophys Acta. 2005 Aug 10;1751(2):213-6.
Bacteriorhodopsin (bR) is solubilized efficiently as a monomer by a novel surfactant, a tripod amphiphile (TPA), which permits the formation of purple hexagonal bR crystals under several conditions. The crystals, although small, diffract to 2.5 A resolution using synchrotron radiation. TPA may be useful for the solubilization, purification, and crystallization of other membrane proteins.
Patents
-
lipidic cubic mesophase crystallization
US
Courses
-
Colloids and Interfacial Science
UW Chemical Engineering
Projects
-
bispecific antibodies
-
Languages
-
French
-
-
German
-
-
cantonese
-
Organizations
-
Penn State Industrial Biotechnology Advisory Board
Board Member
- Present
More activity by Chiu,
-
It was raining and I still wanted to share my doctorate #doctorate #universityofphoenix #dba #doctorbefore50 #rosebudsioux #latina…
It was raining and I still wanted to share my doctorate #doctorate #universityofphoenix #dba #doctorbefore50 #rosebudsioux #latina…
Liked by Chiu, Mark
-
We provide best-in-class analytics to help Bristol Myers Squibb make big decisions every day. Do you have strong problem-solving and communication…
We provide best-in-class analytics to help Bristol Myers Squibb make big decisions every day. Do you have strong problem-solving and communication…
Liked by Chiu, Mark
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Chiu, Mark
8 others named Chiu, Mark are on LinkedIn
See others named Chiu, Mark